Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)
01 Juli 2020 - 10:11PM
Edgar (US Regulatory)
Filed Pursuant to Rule 424(b)(3)
Registration No. 333-234811
PROSPECTUS SUPPLEMENT
NO. 6 DATED JULY 1, 2020
TO
PROSPECTUS DATED
DECEMBER 6, 2019
(AS SUPPLEMENTED)
ARCH THERAPEUTICS, INC.
PROSPECTUS
Up to 17,587,461 Shares of Common Stock
This Prospectus Supplement No. 6 supplements
the prospectus of Arch Therapeutics, Inc. (the “Company”, “we”, “us”,
or “our”) dated December 6, 2019 (as supplemented to date, the “Prospectus”)
with the following attached document which we filed with the Securities and Exchange Commission on July 1, 2020:
|
A.
|
Our Current Report on Form 8-K filed with the Securities and Exchange Commission on July 1, 2020.
|
This Prospectus Supplement No. 6 should be read in conjunction
with the Prospectus, which is required to be delivered with this Prospectus Supplement. This
prospectus supplement updates, amends and supplements the information included in the Prospectus. If there is any inconsistency
between the information in the Prospectus and this prospectus supplement, you should rely on the information in this Prospectus
Supplement.
This Prospectus
Supplement is not complete without, and may not be delivered or utilized except in connection with, the Prospectus, including any
amendments or supplements to it.
Investing in our common stock involves a high degree of risk.
Before making any investment in our common stock, you should carefully consider the risk factors for our common stock, which are
described in the Prospectus, as amended or supplemented.
You should rely only on the information contained in the
Prospectus, as supplemented or amended by this Prospectus Supplement No. 6 and any other prospectus supplement or amendment thereto.
We have not authorized anyone to provide you with different information.
Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete.
Any representation to the contrary is a criminal offense.
The date of this Prospectus Supplement No.
6 is July 1, 2020
INDEX TO FILINGS
|
Annex
|
The Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 1, 2020
|
A
|
ANNEX A
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
July 1, 2020
ARCH THERAPEUTICS, INC.
(Exact name of registrant as specified in
its charter)
Nevada
|
|
000-54986
|
|
46-0524102
|
(State or other jurisdiction
|
|
(Commission
|
|
(I.R.S. Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
235 Walnut Street, Suite 6
|
|
Framingham, Massachusetts
|
01702
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number,
including area code: (617) 431-2313
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
N|A
|
N|A
|
N|A
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.07 Submission of Matters
to a Vote of Security Holders.
On July 1, 2020, the Arch Therapeutics,
Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”) at which
the Company’s proposal to increase the total number of authorized shares of common stock that it may issue from 300 million
to 800 million (the “Charter Amendment Proposal”) was submitted to a stockholder vote. A more detailed description
of the Charter Amendment Proposal is set forth in the Company’s Definitive Proxy Statement filed with the Securities and
Exchange Commission on June 5, 2020.
A total of 140,938,895 shares were
represented in person or by proxy at the Special Meeting, out of 187,862,947 shares outstanding and entitled to vote as of the
record date. Stockholders approved the Charter Amendment, and the following is a tabulation of the voting on the Charter Amendment
Proposal presented at the Special Meeting:
Proposal No. 1 – Proposal to
Increase the Company’s Authorized Capital to 800,000,000 Shares of Common Stock.
Shares Voted For
|
|
Shares Voted Against
|
|
Abstentions
|
103,553,044
|
|
33,707,332
|
|
3,678,519
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ARCH THERAPEUTICS, INC.
|
|
|
|
|
Dated: July 1, 2020
|
By:
|
/s/ Terrence W. Norchi, M.D.
|
|
|
Name: Terrence W. Norchi, M.D.
|
|
|
Title: President, Chief Executive Officer
|
|
|
|
|
|
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
Von Jul 2023 bis Jul 2024